USE OF PARP INHIBITOR IN TREATING CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER

• 1. PARP抑制剂联合VEGFR抑制剂用于治疗卵巢癌或乳腺癌的用途 [P] . 中国专利： CN113874018A . 2021-12-31
• 2. PARP抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途 [P] . 中国专利： CN113768933A . 2021-12-10
• 3. Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer [P] . AU2018380174A1 . 2020-05-21

  机译： PARP抑制剂在治疗耐药性卵巢癌或乳腺癌中的用途

• 4. USE OF PARP INHIBITOR IN TREATING CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER [P] . 世界知识产权组织专利： WO2019109938A1 . 2019-06-13

  机译： 使用PARP抑制剂治疗抗化疗药物的卵巢癌或乳腺癌

• 5. USE OF PARP INHIBITOR IN TREATING CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER [P] . CA3080644A1 . 2019-06-13

  机译： 使用PARP抑制剂治疗抗化疗药物的卵巢癌或乳腺癌

• 1. Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer [J] . Dong Wang, Ruikai Du, Suling Liu 癌症（英文版） . 2017,第006期
• 2. The cancer-testis gene,MEIOB,sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency [J] . Yayun Gu, Cheng Wang, Rongxuan Zhu, 癌症生物学与医学：英文版 . 2021,第001期
• 3. The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency [J] . Yayun Gu, Hongxia Ma, Hongxia Wang, 癌症生物学与医学（英文版 ） . 2021,第001期
• 4. PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells [J] . Yan Shi, Fang Zhou, Feng Jiang, 中国癌症研究（英文版） . 2014,第002期
• 5. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations [J] . Pulliam Nicholas, Fang Fang, Ozes Ali R., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第13期
• 6. PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials [J] . Kamel Dalia, Gray Christopher, Walia Jagdeep Singh, Current drug targets-The International journal for timely in-depth reviews on drug targets . 2018,第1期
• 7. 189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers [J] . N. Nechiporchik, K. Lieb, L. Marquette, European Journal of Cancer Supplements . 2010,第7期
• 8. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1
• 9. Integrating genomics and molecular biology: identifying transcriptional targets for the prostate cancer oncogene SOX4 and evaluating the efficacy of Aurora kinase inhibition in chemotherapy-resistant ovarian cancer [D] . Scharer, Christopher D. 2009
• 10. An Algorithm Combining Patient Performance Status Second Hit Analysis PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive Skin Ovarian and Breast Cancers [O] . Sandy Chevrier, Corentin Richard, Thomas Collot, 2021
• 11. 2003P Molecular diagnostic of BRCA mutations for PARP inhibitors-based therapy: Short time to results using “somatic first” procedure in ovarian and breast cancers [O] . J.L. Merlin, P. Gilson, M. Husson, 2020
• 12. Treatment of BRCA1/2 Hereditary Breast Cancer and Sporadic Breast Cancer with Poly(ADP-ribose) PARP-1 Inhibitors and Chemotherapy [R] . DeSoto, J. A. 2008

• 1. Biological Modulation of Parp Inhibition in Triple Negative Breast Cancer, a Combinational Approach Implementing Multitargeted Epigenetic Therapy (Mtet) with Parp Inhibition, in Advanced Breast Cancer: A Case Study [J] . M. Nezami ,Steve Hager ,Julie Taguchi . 癌症治疗（英文） . 2018,第9期
• 2. 基于晶体结构设计全新PARP1抑制剂的合成及在三阴性乳腺癌中诱导凋亡机制的研究 [C] . 符雷蕾 ,姚大红 ,欧阳亮 . 中国药学会第十三届青年药学科研成果交流会 . 2016
• 3. CDK4/6抑制剂Palbociclib与PARP抑制剂Olaparib联合治疗卵巢癌的有效性及分子 [A] . 易婧妍 . 2020